# SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

> **NCT05177497** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 19 (estimated)

## Conditions studied

- NSCLC, Stage III

## Interventions

- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT05177497
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2024-07
- **Final completion:** 2024-10
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177497, "SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05177497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*